|
Celgene (CELG) Presents Data on Two REVLIMID + Rituximab Studies
StreetInsider.com (subscription) Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas were … |
|
Two Studies Evaluating the Combination of REVLIMID(R) and rituximab in Non …
MarketWatch (press release) Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced that results from two studies evaluating the combination of REVLIMID(R) (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas … Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non …EON: Enhanced Online News (press release) |
Research and Markets: Triple Analysis: Lymphoma, Cancer Vaccines and …The Herald | HeraldOnline.comThis triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Canc…
Research and Markets: Triple Analysis: Lymphoma, Cancer Vaccines and …Fort Mills TimesThis triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) …
Research and Markets: Triple Analysis: Lymphoma, Cancer Vaccines and …Wall Street Journal (press release)This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area…
|
Antibodies in cows could help improve immunology
Texas A&M The Battalion “It was fortuitous through a mutual collaborator of mine at Scripps, down the hall from the guys who started the structural work on these cow antibodies,” said Michael Criscitiello, a co-author of the paper who had originally been working on shark … |
|
GILEAD SCIENCES, INC. : Gilead Announces Interim Phase 2 Data for Idelalisib …
4-traders (press release) … idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing … Gilead Presents Idelalisib DataZacks.com |
Resources offer easy-to-digest tips for gluten-free dietLos Altos Town CrierBecause celiac can be difficult to detect, a blood test for antibodies is needed. Dermatitis herpetiformis, a related skin condition, also requires a gluten-free diet. Accordin…
MedscapeHPV Antibodies in Oral Cancer Patients Long Before DiagnosisMedscapeAbout one third of the patients who went on to develop oropharyngeal cancer associated with human papillomavirus type 16 (HPV 16) had antibodies to the virus detectable in thei…
|
Gilead Presents Idelalisib Data
Zacks.com The patients have not responded to treatments by Roche Holding AG’s (RHHBY) Rituxan (rituximab) and alkylating-agent-containing chemotherapy. The company intends to present detailed data from the study shortly. Overall response rate (ORR) is the … |